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Abstract  
Disorders of facial hyperpigmentation including melasma, post-inflammatory 
hyperpigmentation and solar lentigines are common cutaneous conditions 
which can have a huge impact on patients’ quality of life and often prove 
difficult to treat.  The nascent market of cosmeceutical options provides a 
potentially safer and efficacious alternative for treating these challenging 
conditions. These can be used alone or in combination with other established 
treatments. Many cosmeceutical products are thought to work through 
inhibition of tyrosinase, a key enzyme of melanogenesis.  We discuss the 
mode of action and provide an up-to-date review of the underlying evidence 
base for the top ten cosmeceutical products for hyperpigmentation and 
melasma. Possible safer and more efficacious cosmeceutical therapies we 
discuss include thiamidol, kojic acid, vitamin C, arbutin, retinol, nicotinamide, 
ferulic acid,resorcinol, licorice root extract and soy.  
 
Background 
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Disorders of facial hyperpigmentation are common and can have a profound 
impact upon patients’ quality of life. Melasma is one of the most common 
hyperpigmentary dermatoses with a prevalence estimated to be up to 20% in 
South Asians.1 Due to its high prevalence, it is frequently used as the disease 
paradigm through which treatment of hyperpigmentation is explored. Effective 
treatments for hyperpigmentation disorders are limited with stringent 
photoprotection being the mainstay of prevention. Common treatments 
include hydroquinone, chemical peels, and laser treatments all with varying 
success rates and associated risks.  
 
Cosmeceuticals are cosmetic products that aim to deliver physiologically 
relevant benefits without the incorporation of prescription drugs.2 
Cosmeceuticals are used in disorders of hyperpigmentation, including 
melasma, to target hyperactive melanocytes and impede fundamental steps in 
melanogenesis.1 Cosmeceuticals have gained increased interest with the 
public and dermatological community although their effectiveness and modes 
of actions are not always fully understood. We discuss ten of the most 
commonly used cosmeceuticals for melasma and hyperpigmentation 
disorders,1 reviewing their mode of action and underlying evidence base for 
therapeutic benefit. 
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Melanin is the main pigment in skin produced by melanocytes.3 Tyrosinase is 
an enzyme with a fundamental role in melanogenesis and is a copper-
containing metalloenzyme with dinuclear copper ions, which is fundamental 
as the rate-limiting step in melanogenesis.3 Controlling tyrosinase action is 




Human tyrosinase is fundamental in the formation of melanin. Once 
processed, they become integrated in the melanosomal membrane and are 
therefore responsible for the conversion of tyrosine into melanin.4 Many 
tyrosinase inhibitors have been made available, yet many have variable 
efficacy owing to their discovery based on mushroom tyrosinase as a target.4 
The newly discovered resorcinyl thiazole derivative, thiamidol® (Figure 1a) 
(Beiersdorf AG, Hamburg, Germany) is a powerful human tyrosinase 
competitive inhibitor (table 2), found both in vitro and in vivo to potently, but 
reversibly, inhibit production of melanin.4 Thiamidol® was found to be the 
most potent inhibitor of human tyrosinase and was most efficacious compared 
with 50,000 other possible tyrosinase inhibitors tested.4 Thiamidol® potently 
and reversibly inhibits melanogenesis.4 When compared to hydroquinone 
(2.0%) in a double-blind randomised study, thiamidol® (0.2% in an oil-in-water 
emulsion) was found to be significantly more efficacious than hydroquinone 
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(79% improvement versus 61% improvement respectively) measured using 
the Melasma Area and Severity Index Score (MASI) (p<0.001) (n=80). Self-
assessment of pigmentation was also improved in both groups with no 
reported adverse effects.5 (Table 1)  
 
A separate study investigated the use of thiamidol® in two different trials.6 A 
split-face double blind randomised controlled trial in 34 patients used two 
thiamidol® containing products twice or four times daily on one half of the 
face and SPF30 on the whole face.6 The second trial was a separate single-
arm observational study (n=83) in which patients were treated with SPF30 in 
the day and at night thiamidol® serum and night care cream.6 At 12-weeks, 
hyperpigmentation, skin roughness and MASI all improved significantly 
compared with baseline (-0.78±0.52, -0.87±0.45;p<0.001) in the split-face 
study, whilst in the observational real-life study, skin condition and 
chromametry improved significantly compared to baseline. Self-assessment 
scores also improved significantly from baseline.  The four-times daily 
thiamidol® regimen improved facial hyperpigmentation significantly more than 
the two-times group and was well-tolerated.6 More extensive randomised 
clinical trials that also include males, with post-study follow-ups following 
cessation of treatment are required.5 
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Kojic acid  
Kojic acid (KA) (5-hydroxy-2-hydroxymethyl-4-pyrone; Figure 1b) is a natural 
organic acid and fungal byproduct of some species of Acetobacter, 
Aspergillus and Penicillium.7 KA acts to inhibit tyrosinase genesis with 
additional antioxidant effects and exhibits antimicrobial and anti-ageing 
properties.7 KA can inhibit NF-κB in keratinocytes, whose activation might be 
related to melanogenesis.7 Tyrosinase enzymes contain copper ions in their 
active site and on exposure to ultraviolet radiation (UVR), the copper 
enhances the activity of tyrosinase.8 KA captures this copper ion, preventing 
enhancement of tyrosinase’s activity, thus preventing melanin synthesis.8 
Side-effects associated with hydroquinone have made KA a desirable 
alternative. Currently the European Union’s Scientific Committee on 
Consumer Safety recommends KA to be used at concentrations of 1.0% 
topically.9 Previous studies have used KA at concentrations ranging between 
1-4%; KA was found to be irritant at higher doses.7  
 
Combination treatment of hydroquinone and KA could enhance the inhibition 
of tyrosinase in melasma.10 KA 2% gel (containing 10% glycolic acid (GA) and 
2% hydroquinone) was used on one side of the face of 40 women, whilst the 
other side of the face was treated with the same gel (10% GA and 2% 
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hydroquinone) without KA.10 The addition of KA to the combination gel 
enhanced clearance to 60%, compared to 47.5% without the KA.10 
 
GA is also thought to enhance penetration of KA increasing its effectiveness. 
Garcia and colleagues reported GA and KA combinations to be as efficacious 
as GA and hydroquinone preparations in reducing pigmentation, although the 
authors found KA to be more irritant (n=39).11  
 
KA has proven efficacious in treating photodamage, lentigines and 
hyperpigmented scars.7 Adverse reactions should be considered, with contact 
dermatitis being the main side-effect of KA, as well as increased risk of 
sunburn in individuals with sensitive skin.7 There is some evidence from 
animal studies that ingestion and systemic absorption of KA may be 
carcinogenic, but this has not been reported with topical formulations;7 it 
remains prudent to avoid applying KA to broken skin.   Future studies are 
required to fully evaluate the safety profile of KA as a lightening treatment.7 
 
Vitamin C  
Humans rely solely on external supplementation to get supplies of vitamin C 
such as through oral intake or in cutaneous applications through topical 
administration in cosmeceutical products.12 Vitamin C (Figure 1c) is available 
in several formulations. L-ascorbic acid is the most biological active form and 
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is used in many cosmeceutical products.12 Other common vitamin C 
derivatives include: ascorbyl-6-palmitate, magnesium ascorbyl phosphate, 
disodium isostearyl 2-0 L-ascorbyl phosphate, ascorbic acid sulphate and 
tetra-isopalmitoyl ascorbic acid.12 
 
One of the main difficulties with vitamin C products is instability.12 The most 
stable formulation of vitamin C is L-ascorbic acid with a pH of 3.5, as acidity 
improves its penetration and stability. Vitamin C is most efficacious at 
concentrations greater than 8% and at concentrations greater than 20% was 
found to cause irritation.12  
  
Vitamin C is thought to inhibit tyrosinase by interacting with copper ions at 
tyrosinase active sites, decreasing melanogenesis.12 A lipophilic pro-vitamin 
C, tetra-isopalmitoyl ascorbic acid (VC-IP), was found to have antioxidant 
properties and was able to suppress melanocyte proliferation from UVB-
irradiated keratinocytes in vitro.12 C’ensil® (Sage Pharmeceuticals Inc., 
Shreveport, LA) containing 25% L-ascorbic acid was developed to promote 
absorption of L-ascorbic acid into the skin, since it is normally rapidly oxidised 
into an aqueous solution.13 Melasma patients treated with C’ensil (n=40) had 
a significant decrease in their MASI scores and an increase in their quality of 
life scores.13 
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In a separate study, 5% L-ascorbic acid was compared with 4% hydroquinone 
cream in 16 women with melasma. Hydroquinone was superior in subjective 
measurements than ascorbic acid (93% good and excellent results versus 
62.5% respectively, p<0.05).14 There was no statistical difference in 
colorimetric measures, but side-effects were much greater in the 
hydroquinone group (68.5% versus 6.2% respectively).14 A combination of 
procyanidin (24mg) and vitamins A (6mg), C (60mg) and E (15IU) was found 
to be safe and efficacious among 80 women with melasma in a randomised, 
double-blind, placebo-controlled trial.15 
 
In a split-face comparative study of 30 melasma patients,16 20% Vitamin C 
with microneedling on one side of the face was compared with tranexamic 
acid (4mg/mL) and microneedling on the other side, given twice a month for 
eight weeks.16 Both treatments were effective and safe and microneedling 
ensured that there is uniform delivery of ingredients.16 
 
Another study of 30 patients found microneedling (six sessions) with topical 
vitamin C to be a significantly effective and safe treatment, particularly for 
those of Fitzpatrick skin types I-III.17  
 
In a separate study, patients were treated with full-face iontophoresis mask 
and vitamin C (ascorbyl glucoside) preparation.18 Patients had one treatment 
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and 12-24 home treatments over 1-2 months with sun avoidance advised.18 
This treatment produced a mean improvement of 73% in abnormal 
pigmentation with a mean improvement of MASI of 15.7.18  
 
Vitamin C appears to be an effective treatment option for patients suffering 
from melasma or post-inflammatory hyperpigmentation.18 Its long-term 
efficacy remains unknown and large randomised controlled trials with longer 
follow-ups are required to see if any benefits of treatment can be 
maintained.18 Sunscreens are only partially efficacious for blocking free 
radicals released upon UV exposure. Vitamin C works synergistically with 
sunscreens to enhance their photoprotective effect.12           
 
Arbutin 
Alpha and β-arbutin (Figure 1d) are derivatives of hydroquinone extracted 
from the bearberry plant leaves with smaller quantities found in smaller 
quantities in cranberry and blueberry leaves.19 Arbutin is a natural 
gluconopyranoside which reduces tyrosinase activity in addition to inhibition of 
melanocyte maturation in the absence of toxicity.20 The tyrosinase inhibitor 
deoxyArbutin inhibits tyrosine hydroxylase in a dose dependent way, inhibiting 
melanogenesis hence its use in skin-lightening of hyperpigmented skin.20 
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Serratulae quinquefoliea folium, plant extract is a new source of β-arbutin and 
was used in a randomised controlled trial of 102 women with melasma and 
solar lentigines.21 A cream containing 2.51% arbutin was applied twice a day 
for eight weeks and lightening and skin tone homogenisation was found in 
66% of patients.21 In a separate study, 66.67% patients treated with Nd:YAG 
laser and topical 7% alpha arbutin solution had good or excellent clearance of 





Vitamin A and its derivatives (retinoids) are used as topical formulations in 
anti-ageing.23 Non-prescribed, cosmeceutical retinoids are natural or synthetic 
products such as retinol, retinyl-palmitate, retinyl-acetate, and retinaldehyde.23 
 
Retinoids exert their effects in pigmentation through a number of mechanisms 
which include: inhibition of matrix metalloproteinase activation, inhibition of 
oxidative stress, decreased melanosome transfer, and through regeneration 
of the extracellular matrix.23 In addition, retinoids regulate keratinocyte 
differentiation aiding in accelerated exfoliation and consequently affects 
melanin count in the epidermis.23 Thinning of the stratum corneum through 
use of retinoids can increase the permeability and hence penetration of 
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depigmenting products in the epidermis, increasing their bioavailability, thus 
promoting depigmentation.23  
 
Improvements in the MASI were found after four weeks treatment in melasma 
and photodamaged skin, with a 4% hydroquinone and cosmetic 1% retinol 
combination (n=31).24 In a small study (n=21), 10% all-trans retinol gel, 5% 
hydroquinone and 7% lactic acid produced a 89% clinical improvement in 
patients with skin pigmentation.25          
 
Retinyl-acetate and retinyl-palmitate are vitamin A ester derivatives, thought 
to be the least effective of the topical retinoids. Retinyl propionate and retinyl 
palmitate have been trialled in photoaging creams with inconclusive 
findings.26-27 Retinol (Figure 1e) is a precursor of retinaldehyde and is derived 
from the hydrolysis of beta-carotene; the molecule exhibits a depigmenting 
action and its use is supported by a weak evidence base.  
 
Retinaldehyde (Figure 1f) is a retinoic acid precursor, found to have 
depigmenting properties.23 Retinaldehyde has been used in anti-aging 
treatments to reduce wrinkles at concentrations of 0.05%, which appears 
effective and more tolerable, with less irritation compared to tretinoin.23 
In animal studies, retinaldehyde decreased melanin concentration in guinea 
pig ears and mice tails by 54% and 74% respectively, decreasing the active 
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melanocyte count by 42% and 77% respectively.  The authors hypothesise 
this action is likely due to disruption of melanocyte pathways rather than direct 
melanocyte toxicity.28 Studies which demonstrate the effects of retinaldehyde 
in melasma are lacking. Large randomised controlled trials are necessary to 
explore cosmeceutical retinols and retinaldehydes in patients with melasma 
and pigmentation. From the current available evidence, retinyl-acetate and 
retinyl palmitate are unlikely to have significant efficacy in pigmentation, 
retinaldehydes need further research and retinol appears promising in treating 
pigmentation.23 
 
Bakuchiol is a purified mereoterpene phenol found in seed and plant sources 
recently found to have anti-proliferative and anti-inflammatory properties.29 In 
a randomised, double-blind 12-week study (n=44), patients were given either 
bakuchiol 0.5% cream twice daily or retinol 0.5% cream.29 Both treatments 
significantly decreased hyperpigmentation and wrinkle surface area with no 
statistically significant difference between compounds. The retinol treatment 
led to greater facial skin scaling and stinging.29 As further evidences accrues, 








Nicotinamide (Figure 1g), also referred to as niacinamide, is a water-soluble 
amide of vitamin B3.30 Nicotinamide is thought to act as an antioxidant 
through polyadenosine diphosphate-ribose polymerase inhibition in addition to 
melanosome transfer inhibition.30 
 
A cream containing a combination of nicotinamide 4%, arbutin 3%, bisabolol 
1% and retinaldehyde 0.05% was found to be successful in reducing MASI 
and total melasma surface area (n=35) at 30 days with a further decrease at 
60 days (p=0.001).19 Patient satisfaction was also improved significantly, 
75.8% of participants were dissatisfied with their skin appearance at baseline 
versus 15.2% at day 60.19  
 
A separate study randomised 27 patients to receive 4% nicotinamide cream 
on one side of the face and 4% hydroquinone on the other side for four 
weeks.31 All patients had improvements in their pigmentation and MASI score 
decreased by 70% and 62% in the hydroquinone and nicotinamide groups 
respectively, but this difference was not statistically significant.31 Nicotinamide 
reduced mast cells infiltrates and improved solar elastosis in patients with 
melasma with a lower side-effect profile.31  
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Nicotinamide is gaining increasing attention due to its skin-lightening effects 
and stimulation of DNA repair as well as its ability to inhibit UV 
photocarcinogenesis.30 Further research is required to substantiate its use as 
monotherapy in pigmentary disorders in large trials.  
 
Ferulic acid 
Ferulic acid (FA) (Figure 1h) is part of the phenolic acid group found in plants 
and is a cinnamic acid derivative.32 It is commonly found in whole grains, 
spinach, parsley, grapes, apples, rhubarb, oats, rye and barley.32 FA has 
antioxidant properties with low irritancy.32 Human endothelial cells and 
keratinocytes treated with FA prior to UVA radiation were less vulnerable to 
free radical damage through prevention of UV-induced cell cycle modifications 
and regulation of DNA repair genes supporting its anti-oxidant effects.32 
FA is used in skin lightening formulations because of its ability to inhibit 
tyrosinase and inhibit melanocyte proliferation.32 FA can maintain a high local 
concentration with low metabolism, penetrating deep into the skin.32 Its high 
penetrating ability is likely due to the lipophilic properties of this acid.32 Its 
recommended cosmeceutical concentration is 0.5-1%.32 
 
Several studies have found FA to be useful in combination formulations, such 
as with oral vitamin C, E, azelaic acid, mandelic acid, phytic acid, and 4N-
butyl resorcinol.34-36 A combination of 20% azelaic acid, mandelic acid, phytic 
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acid, 4N-butyl resorcinol, and FA was found to be the most effective 
combination in treating pigmentation in 60 women with melasma.35 
Overall, FA’s potent antioxidant properties make it a desirable treatment 




Resorcinols are effective tyrosinase inhibitors.37 4-n-Butylresorcinol (Figure 
1i), is a derivative of resorcinol and has been used in depigmentation 
treatments. Okubo and colleagues reported that 4-n-butylresocinol has 
inhibitory effects on melanogenesis through direct inhibition of tyrosinase 
activity and synthesis.38 Subsequent in vitro studies have revealed 4-n-
butylresocinol’s ability to inhibit melanin synthesis and activation of tyrosinase 
and tyrosinase-related protein-1.39 This inhibition was found to be more potent 
than hydroquinone, arbutin and KA monotherapy.37 
 
In a study, patients treated with 4-n-butylresocinol had significantly lower 
pigmentation scores than vehicle-treated skin (n=32), with a baseline 
pigmentation score of 7.5±1·9 reduced to a score of 6.2±2.3 at 12-weeks in 
the treated group (p=0.027).40 This efficacy was replicated in a separate study 
in which melasma patients were given 4-n-butylresocinol cream 0.1%, to 
apply to each side of the face twice daily for eight weeks (n=20).41 A 
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statistically significant decrease in the mean melanin index was found in those 
treated with 4-n-butylresocinol (3.43%) compared with vehicle treated skin 
(0.15%) (p=0.006).41 Reported side-effects included mild erythema and itching 
seen in two patients.41  
 
Madan Mohan and colleagues also treated melasma patients with twice daily 
4-n-butylresorcinol 0.3% cream for eight weeks (n=52).42 MASI score 
significantly decreased from baseline score of 14.73±0.59 to 11.09±0.53 after 
week four (p<0.001) and 6.48±0.43 at week eight (p<0.001), with no adverse 
events reported.42 Overall, 4-n-butylresorcinol appears to be a safe and 
efficacious treatment option for melasma. 
  
Resorcinol, combined with salicylic acid and lactic acid in ethanol is commonly 
used in chemical peels for lightening often in combination with Trichloroacetic 
acid (TCA), called Jessner’s solution. This combination allows more uniform 
penetration, better peeling with a smaller and safer concentration of TCA.43 
 
Licorice root extract 
Licorice (Glycyrrhiza glabra) has been shown to contain hydrophobic 
fractions, with flavonoids which partially inhibit melanogenesis, likely due to 
tyrosinase inhibition.44 Glabridin is the main component of the hydrophobic 
part of liquorice extract with cutaneous activity, which has shown to inhibit 
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tyrosinase activity in animal models.45 Another active ingredient of licorice 
root, liquiritin, reduces UV-induced erythema, has an anti-inflammatory effect 
and has an inhibitory effect on melanosomes.46 
 
The efficacy of topical 2% liquiritin, topical 4% liquiritin, and topical 4% 
hydroquinone was compared (n=90). Topical 4% liquiritin was reported as 
being more effective than 2% liquiritin and 2% topical liquiritin was reportedly 
more efficacious than 4% hydroquinone.46 In a separate study, melasma 
patients were treated with liquiritin on one side of their face and vehicle cream 
on the other twice daily for four weeks (n=20). 80% of patients showed an 
excellent response to treatment on the liquiritin side.47 
 
A subsequent study, compared hydroquinone 2% cream used once a day with 
emblica, licorice and belides combination cream used twice daily.47 A similar 
improvement in melasma was seen in both groups (88.9%, and 78.3% 
respectively) which were statistically significant from baseline (p<0.001).48 
There were similar improvements in both groups in terms of the MASI.47 This 
study suggests that combination treatment of emblica, licorice and belides, 
might be a safe and efficacious alternative to hydroquinone.48       
Overall, licorice extracts might be a natural beneficial treatment for 
hyperpigmentation and larger randomised controlled trials are required to 
support this. 




Natural soybeans contain the small proteins Bowman-Birk inhibitor and 
soybean trypsin inhibitor in addition to isoflavanes and serine proteases which 
have demonstrated anti-senescent, antioxidant, pigment attenuating, 
photoprotecting and melanosome transfer inhibiting properties.49 It possibly 
exerts its effects through interaction with the protease-activated receptor 2 
(PAR-2).49 Inhibition of this pathway reduced melanosome phagocytosis by 
keratinocytes leading to reduced melanin transfer leading to reduced skin 
pigmentation.49 A randomised controlled trial found a soy containing 
moisturiser to be significantly more efficacious than a vehicle product in 65 
women with facial pigmentation damage after 12 weeks of treatment with 
improvements in pigmentation, blotchiness, dullness, fine lines, overall 
texture, skin tone and overall appearance.50 Hermanns et al found soybean 
extract to have skin-lightening effects in men suffering from facial 
hyperpigmentation after three weeks of treatment (n=44).51 Pierard and 
colleagues also beneficial effects of soy extract for 16 melasma patients after 
once daily application for three months.52 Treated lesions demonstrated an 
average reduction in hyperpigmentation by 12% and 87.5% of patients had 
improvements in their pigmentation.52  
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Conclusion 
Management of hyperpigmentation disorders including melasma is often 
challenging, requiring protracted treatments with various agents. The use of 
cosmeceuticals has the potential to treat hyperpigmentation in a perceptibly 
more ‘natural’ way, with fewer adverse effects associated with more 
established treatments such as hydroquinone. Whilst we acknowledge our list 
is not exhaustive, thiamidol, KA, vitamin C, arbutin, retinol, nicotinamide, FA 
and resorcinol have promising potentials in the treatment of melasma and 
disorders of pigmentation and are suitable as monotherapy or in combination 
with other treatment modalities. These substances appear both efficacious 
and safe with only minor side-effects reported with supportive evidence for 
their use from small in vivo and in vitro studies. However, large randomised 
controlled trials with long follow-ups are lacking. Future research should focus 
on the exploitation of natural substances with hypopigmentary properties to 
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Table 2. Mechanism of action of cosmeceuticals 
Cosmeceutical Mechanism of Action References 




Kojic Acid Inhibits tyrosinase 




Vitamin C Tyrosinase inhibition 
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copper ions at 
tyrosinase active sites, 
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Soybean Contains isoflavanes 





















































Figure 1. Chemical structures of cosmeceuticals. Adapted from (4). Images created 
using https://chem-space.com/search 
 
1a.Thiamidol 1b.Kojic Acid 1c. Vitamin C 
1d. Arbutin 1e. Retinol 1f. Retinaldehyde 
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